FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D. **SECTION 4(6), AND/OR** 

OMB APPROVAL

OMB Number: 3235-0076


April 30, 2008 Expires:

Estimated average burden hours per response...... 16.00

SEC USE ONLY

Serial

Prefix



#### GENERAL INSTRUCTIONS

#### Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

### State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTI	ΛN

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

	A. BA	SIC IDENTIFICATION	N DATA		
<ul> <li>Enter the information requested for the</li> <li>Each promoter of the issuer, if th</li> <li>Each beneficial owner having the</li> <li>Each executive officer and direct</li> <li>Each general and managing partr</li> </ul>	e issuer has been organized power to vote or dispose, or of corporate issuers and	or direct the vote or dispo	sition of, 10% o	or more of a class of equity securities of the issuers of partnership issuers; and	er;
Check Box(es) that Apply:  Promoter	Beneficial Owner	Executive Officer		☐ General and/or Managing Partner	
Full Name (Last name first, if individual) Steven J. Mento					
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365)					
Check Box(es) that Apply: Promoter	Beneficial Owner		Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Charles J. Cashion					
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365)					
Check Box(es) that Apply:  Promoter	Beneficial Owner	☑ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual) Alfred P. Spada					
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365)					
Check Box(es) that Apply:  Promoter	Beneficial Owner	☑ Executive Officer	☐ Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Jennifer Giottonini Cayer					
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365)	-	•			
Check Box(es) that Apply:  Promoter	Beneficial Owner	☐ Executive Officer	□ Director	General and/or Managing Partner	<u> </u>
Full Name (Last name first, if individual) David Hale	·				
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365)		•			
Check Box(es) that Apply:  Promoter	Beneficial Owner	Executive Officer	□ Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Paul Klingenstein					
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365)	, , ,	•			
Check Box(es) that Apply:  Promoter	Beneficial Owner	Executive Officer	☑ Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Patrick Lee				-	
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365)		•			
	(Use blank sheet, or copy	and use additional copies	of this sheet, as	necessary.)	

,	A. BA	SIC IDENTIFICATION	DATA	
Enter the information requested for the     Each promoter of the issuer, if the     Each beneficial owner having the     Each executive officer and directe     Each general and managing partners.	e issuer has been organized power to vote or dispose, or of corporate issuers and	or direct the vote or dispo	sition of, 10% o	r more of a class of equity securities of the issuer; ers of partnership issuers; and
Check Box(es) that Apply:  Promoter	☑ Beneficial Owner	Executive Officer	□ Director	General and/or Managing Partner
Full Name (Last name first, if individual) William Gerber				
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365 E				
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Aberdare Ventures III, L.P.				
Business or Residence Address (Number of One Embarcadero Center, Suite 4000, Sa		Code)		
Check Box(es) that Apply:  Promoter	Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Bay City Capital Fund IV, L.P.				
Business or Residence Address (Number 750 Battery Street, Suite 400, San Francis		Code)		
Check Box(es) that Apply:  Promoter	☑ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Advent Private Equity Fund IV				
Business or Residence Address (Number 25 Buckingham Gate, London, United Ki		Code)		
Check Box(es) that Apply:	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Steven J. Mento and Linda A. Mento as T	Trustees under the Ment	o Family Trust Dated De	cember 29, 199	24
Business or Residence Address (Number a 16036 Country Day Road, Poway, CA 92		Code)		
Check Box(es) that Apply:  Promoter	☑ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Charles J. Cashion and Martha Diane Ca or any Successor Trustee thereunder	ishion, as Trustee UDT I	Dated July 27, 1988, whe	rein Charles J.	Cashion and Martha Diane Cashion are Trustors,
Business or Residence Address (Number 18778 Olmeda Place, San Diego, CA 9212		Code)		
Check Box(es) that Apply:  Promoter	⊠ Beneficial Owner	Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual) The Paul E. Cayer and Jennifer G. Cayer	r Trust Dated March 1, 2	2005		
Business or Residence Address (Number 14112 Bahama Cove, Del Mar, CA 92014		o Code)		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

	A. BA	SIC IDENTIFICATION	DATA	
<ul> <li>Enter the information requested for the</li> <li>Each promoter of the issuer, if the</li> <li>Each beneficial owner having the</li> <li>Each executive officer and directo</li> <li>Each general and managing partner</li> </ul>	issuer has been organized power to vote or dispose, or of corporate issuers and	or direct the vote or dispo	sition of, 10% o	r more of a class of equity securities of the issuer; ers of partnership issuers; and
Check Box(es) that Apply: Promoter	☑ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Hale BioPharma Ventures LLC				
Business or Residence Address (Number a 1042-B N. El Camino Real, Suite 430, End		Code)		
Check Box(es) that Apply:  Promoter	Beneficial Owner	Executive Officer	□ Director	General and/or Managing Partner
Full Name (Last name first, if individual) Marc Perret				
Business or Residence Address (Number a c/o Conatus Pharmaceuticals Inc., 4365 E				
Check Box(es) that Apply:  Promoter	Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Coöperatieve Gilde Healthcare II U.A.		•-		
Business or Residence Address (Number a c/o Gilde Healtheare Partners, Newtonlaz			herlands	
Check Box(es) that Apply:  Promoter	☐ Beneficial Owner	Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				
Business or Residence Address (Number a	and Street, City, State, Zip	Code)		
Check Box(es) that Apply:  Promoter	☐ Beneficial Owner	Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				
Business or Residence Address (Number a	and Street, City, State, Zip	Code)		
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual)				
Business or Residence Address (Number a	and Street, City, State, Zip	Code)		
Check Box(es) that Apply: Promoter	☐ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual)				
Business or Residence Address (Number a	and Street, City, State, Zip	Code)		,
<u> </u>	(Use blank sheet, or copy	and use additional copies	of this sheet, as	necessary.)

	1				B. INFORM	ATION ABO	OUT OFFER	RING				
	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?  Answer also in Appendix, Column 2, if filing under ULOE.  What is the minimum investment that will be accepted from any individual?										No . ⊠	
	Does the offering permit joint ownership of a single unit?									Yes	No No	
3. Does	the offering p	permit joint o	wnership of a	single unit?				,			⊠	
remur persor than f	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.											
	e (Last name t applicable.	first, if indiv	idual)									
Business	or Residence	Address (Nu	mber and Str	eet, City, Sta	ue, Zip Code)	)						
Name of	Associated B	roker or Deal	ler									-
			Solicited or In									
AL   IL   MT   RI	All States of AK AK IN NE SC	AZ  IA  IA  NV  SD	AR  KS  NH  TN	□ CA □ KY □ NJ □ TX	CO LA NM UT	CT ME NY VT	□ DE □ MD □ NC □ VA	DC MA ND WA	□ FL □ MI □ OH □ WV	□ GA □ MN □ OK □ WI	□ HI □ MS □ OR □ W	☐ ID S ☐ MO L ☐ PA
Full Name	e (Last name	first, if indiv	idual)									
Business	or Residence	Address (Nu	mber and Str	eet, City, Sta	ite, Zip Code)							
Name of	Associated B	roker or Deal	er									
			Solicited or In			=						
AL IL MT RI	☐ AK ☐ IN ☐ NE ☐ SC	AZ IA INV SD	AR KS NH TN	□ CA □ KY □ NJ □ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	□ FL □ MI □ OH □ WV	☐ GA ☐ MN ☐ OK ☐ WI	□ HI □ MS □ OR □ W	_ □ ID S □ MO L □ PA
Full Name	e (Last name	first, if indiv	idual)									
Business	or Residence	Address (Nu	mber and Str	eet, City, Sta	ite, Zip Code)	)						
Name of A	Associated B	roker or Deal	er									
			Solicited or In			rs						
AL IL MT	☐ AK ☐ IN ☐ NE ☐ SC	AZ IA NV SD	AR KS NH	CA KY NJ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	□ FL □ MI □ OH □ WV	GA MN OK WI	HI   MS   OR   W	□ID □MO □PA

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

# C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \( \square\$\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.		
	Type of Security	Aggregate Offering Price	Amount Already Sold
	Debt	\$0.00	<u>\$0.00</u>
	Equity <sup>(1)</sup>	\$31,870,663.5	<u>\$7,870,663.50</u>
	☐ Common ☐ Preferred ☐ Series A	\$0.00	\$0.00
	Convertible Securities (including warrants)	\$0.00	<u>\$0.00</u>
	Partnership Interests	\$0.00	\$0.00
	Other (Specify)	\$0.00	\$0.00
	Total	\$31,870,663.5	<u>\$7,870,663.50</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		٩
		Number Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	<u>25</u>	\$7,870,663.50
	Non-accredited Investors	_0_	\$0.00
	Total (for filings under Rule 504 only)		<del></del>
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		Dellas Assault
	Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		
	Regulation A		
	Rule 504		
	Total		
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	C	<u>\$0.00</u>
	Printing and Engraving Costs		\$0.00
	Legal Fees		\$121,000.00
	Accounting Fees		\$0.00
	Engineering Fees		\$0.00
	Sales Commissions (specify finders' fees separately)		\$0.0 <u>0</u>
	Other Expenses (identify)		<u>\$0.00</u>
	Total	N.	\$121,000,00

(1) On November 20, 2006, pursuant to a stock acquisition agreement, the issuer issued to F. Hoffman-La Roche Ltd and Roche Palo Alto LLC 333,333 shares of Series A Preferred Stock and committed to issue to F. Hoffman-La Roche Ltd an additional 2,666,666 shares of Series A Preferred Stock upon the occurrence of a certain event, in partial consideration for certain license rights acquired by the issuer from F. Hoffman-La Roche and Roche Palo Alto LLC. Each share of Series A Preferred Stock was valued at \$0.75 per share.

	•						
	C. OFFERING PRICE, N	JMBER OF INVESTORS, EXPENSES AND USE C	)F P	ROCEE	DS		
5.	b. Enter the difference between the aggregate offering total expenses furnished in response to Part C - Question to the issuer."  Indicate below the amount of the adjusted gross proceeds to purposes shown. If the amount for any purpose is not know	4.a. This difference is the "adjusted gross proceeds to the issuer used or proposed to be used for each of the					<u>\$31,749,663.50</u>
	estimate. The total of the payments listed must equal the adj Part C - Question 4.b above.			Off Direc	nents to icers, ctors, & iliates		Payments to Others
	Salaries and fees			\$0.00			<u>\$0.00</u>
	Purchase of real estate			<u>\$0.00</u>			<u>\$0.00</u>
	Purchase, rental or leasing and installation of machin	ery and equipment		<u>\$0.00</u>			<u>\$0.00</u>
	Construction or leasing of plant buildings and facility	es		\$0.00			\$0.00
	•						\$0.00 \$0.00
	• • •						
			u	\$0.00		M	\$31,749,663.50
	Other (specify):			<u>\$0.00</u>			<u>\$0.00</u>
	Column Totals		П	\$0.00		l⊠i	\$31,749,663.50
	totals		Ļ	<u> </u>			<u> </u>
	Total Payments Listed (column totals added)				×	\$31,749,	663.50
		D. FEDERAL SIGNATURE	_			•	
an ı	issuer has duly caused this notice to be signed by the und indertaking by the issuer to furnish to the U.S. Securities non-accredited investor pursuant to paragraph (b)(2) of R	and Exchange Commission, upon written request of	unde	er Rule 50 taff, the in	)5, the f	following si	ignature constitute led by the issuer to
	er (Print or Type) natus Pharmaceuticals Inc.	Signature Naul F. March			Date	12/30	106
Nar	ne of Signer (Print or Type)	Title of Signer (Print or Type)			·		
Cha	rles J. Cashion	Senior Vice President, Finance, Chief Financial Offic	er,	Secretary	and T	reasurer	
	t						

#### ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

1.		230.262 presently subject to any of the disqualification provisions  Yes No
	,	See Appendix, Column 5, for state response.
2.	The undersigned issuer hereby und at such times as required by state l	dertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) aw.
3.	The undersigned issuer hereby und	dertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
4.	The undersigned issuer represent Exemption (ULOE) of the state in establishing that these conditions h	s that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of have been satisfied. N/A
The iss person.		nows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized
Issuer (	(Print or Type)	Signatule, lact / la Date
Conatu	us Pharmaceuticals Inc.	1 Charles 18401 1430/06
Name (	(Print or Type)	Title (Print or Type)
Charle	s J. Cashion	Senior Vice President, Finance, Chief Financial Officer, Secretary and Tressurer

E. STATE SIGNATURE

### Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

# APPENDIX

1		2	3	.=		4		,	5	
	non-ac investor	to sell to credited s in State	Type of security and aggregate offering price offered in state (Part C-Item 1)		Type of investor and amount purchased in State					
	:		Aggregate Amount of Series A Preferred	Number of Accredited		Number of Non- Accredited			-Item 1)	
State-	Yes	No	Stock to be sold	Investors	Amount	Investors	Amount	Yes	No	
	<u></u>	ļ			ļ <u>.</u>				<u> </u>	
AK		,								
AZ									<u> </u>	
AR								_		
CA		Х	\$17,243,163.00	14	\$5,243,163	0	\$0.00		Х	
СО										
СТ	=							_		
DE.										
DC							-	_		
FL				<del>-</del>						
GA					<del></del>					
НІ				<del></del>						
ID	,									
IL.			-	<u> </u>					-	
ΙΝ	_									
IA								1.		
KS			-					<u>·</u>		
KY				<del></del>				_		
LA		_		<del></del>	<u> </u>					
ME						<del>-</del>				
MD										
MA	:		· ;						-	
MI							-			
MN	;									
MS							-			
МО								_		

# APPENDIX

			<del></del>	<del></del>	· · · · · · · · · · · · · · · · · · ·						
1		2	3			4	•	:	5		
	Intend to sell to non-accredited investors in State (Part B Item 1)		Type of security and aggregate offering price offered in state (Part C-Item 1)	Type of investor and amount purchased in State (Part C-Item 2)					Disqualification under State ULOE(if yes, attach explanation of waiver granted) (Part E-Item 1)		
				N ) 6		Number of					
			Aggregate Amount of Series A Preferred	Number of Accredited		Non- Accredited					
State	Yes	No	Stock to be sold	Investors	Amount	Investors	Amount	Yes ·	No		
MT	ļ			<del></del>		-		· ·			
NE								<u>_</u>			
NV											
NH											
NJ											
NM											
NY											
NC											
ND			,				,				
ОН						<u> </u>					
ОК											
OR											
PA											
RI											
SC											
SD											
TN											
TX			· ·								
UT											
VT											
VA											
WA				· ·							
wv											
WI											
WY											
PR							· · · · · · · · · · · · · · · · · · ·				
·						<del></del>					